Retrospective analysis shows poor progression-free survival in large B-cell lymphoma post CD19-CAR-T, highlighting bispecific antibodies' potential as targeted treatments.
Key Points
Overall response rates in subsequent therapies for large B-cell lymphoma were up to 55.6% for polatuzumab-based regimens, indicating variability in treatment efficacy.
Prognostic factors like LDH levels and ECOG performance status significantly influenced overall survival after CAR-T therapy failure.
A single-center retrospective analysis was performed involving 187 patients with relapsed/refractory large B-cell lymphoma.
Further investigation is needed to refine therapeutic strategies for large B-cell lymphoma after CD19-CAR-T failure.
Cite This Study
Kungwankiattichai et al. (2025) studied this question.